IVIRMA’s scientific innovation continues to revolutionize the industry
IVI was founded in 1990 by Professors José Remohí and Antonio Pellicer, and became a leader in fertility treatment in Europe and Latin America.
Its success rates have been one of the best in the sector since its inception, thanks to its continuous efforts in the teaching and research fields, which have put this company on the international vanguard of fertility care.
RMA was founded in 1999 by Drs. Paul Bergh, Richard Scott and Michael Drews, quickly becoming a leader in reproductive medicine in the United States.
Its success rates were consistently higher than the national average, thanks to cutting-edge research and state-of-the-art technology, and the group was soon recognized as a leader in the Americas.
IVI and RMA merged in 2017, a turning point that transformed the assisted reproduction industry, creating the only global company in Europe, the United States and Latin America. The company has finished 2020 with 65 clinics and more than 56,000 assisted reproduction treatments.
IVI and RMA both place great importance on research, high-quality scientific results, and a common culture with a single objective: to achieve the best results for patients.
MOST RELEVANT MILESTONES
1990 - 1999
ICSI with testicular biopsy
Pregnancy from frozen testicular sperm
Cytoplasmic transfer for poor oocyte quality
Clinical metabolomic assessment of spent culture media to predict delivery
Cryotop oocyte vitrification study
Rapid 24 chromosome PGT-A pregnancy
Baby born after using Embryoscope data for embryo selection
2000 - 2010
2011 - 2014
Trial showing that single embryo transfer with PGT-A attains equivalent pregnancy rates to multiple embryo transfers
Trial evaluating the safety of embryo biopsy
Prospective assessment of the predictive value of PGT-A results non-selection study
Study shows birthweight of IVF singletons are approximately equal to national percentiles
Trial using NexGen sequencing-based PGT-A
Trial evaluating autologous mitochondrial transfer to oocytes
Three pregnancies from ovarian rejuvenation / activation
NexGen PGT-A non-selection study: Demonstrates extreme high predictive value of aneuploidy screening results, and is only validated assay in the world
Prospective study demonstrating stimulated IVF as safe as natural cycle IVF